EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Programming regulated cell death to engineer whole-tumor-cell vaccines for cancer immunotherapy

Yingchao Guan, Die Bai, Na Bu, Wenhui Hao, Yasen Maimaitiyiming

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-09 · 1881 (4) · 189640

DOI: 10.1016/j.bbcan.2026.189640 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-09. Verfasst von Yingchao Guan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi 830011, Xinjiang, China; Xinj…. Hauptthemen laut MEDLINE: Cancer Vaccines, Neoplasms, Immunotherapy, Regulated Cell Death. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 213 Literaturangaben. Gefördert von: Xinjiang Medical University, Xinjiang Uyghur Autonomous Region People's Government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Regulated cell death (RCD) encompasses a variety of genetically controlled cell death programs that are essential for maintaining tissue homeostasis and have emerged as promising therapeutic targets in oncology. When used to prepare whole-tumor-cell (WTC) vaccines, dying cancer cells provide broad tumor-antigen repertoires together with damage-associated molecular patterns (DAMPs) that can function as endogenous adjuvants. This review examines how distinct RCD pathways shape antitumor immunity and how they can be exploited to engineer next-generation WTC vaccines. We summarize the molecular and immunological features of major RCD modalities, including apoptosis, necroptosis, pyroptosis, ferroptosis, cuproptosis, and emerging forms of regulated death, emphasizing their divergent capacities to promote antigen uptake, dendritic-cell activation, cross-presentation, and T-cell priming. We also discuss key translational barriers, including tumor heterogeneity, immunosuppressive tumor microenvironments, variable sensitivity to RCD induction, empirical inactivation methods, and the lack of mechanism-informed potency assays. Particular attention is given to the safety challenge posed by highly inflammatory modalities such as necroptosis and pyroptosis, which require careful control to balance immunogenic potency with hyperinflammation or systemic toxicity. Future development should shift from procedure-defined tumor-cell killing toward precision RCD programming, quantitative validation of immunogenic "death fingerprints," rational combinations with immune-checkpoint blockade or microenvironment modulating therapies, and individualized optimization guided by dynamic immune monitoring. By clarifying the interplay between RCD and antitumor immunity, this review provides a framework for designing reproducible, mechanism-guided, and clinically translatable WTC vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesNeoplasmsImmunotherapyRegulated Cell DeathHumansAnimalsTumor MicroenvironmentNecroptosisCuproptosisAntigens, Neoplasm

Stichwörter der Autor:innen

Cancer immunotherapyDamage-associated molecular patterns (DAMPs)Immunogenic cell death (ICD)Regulated cell death (RCD)Tumor antigensWhole-tumor-cell (WTC) vaccine

Substanzen

Cancer VaccinesAntigens, Neoplasm

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi 830011, Xinjiang, China; Xinjiang Key Laboratory of Molecular Biology for Endemic Diseases, Xinjian…
  • Xinjiang Key Laboratory of Molecular Biology for Endemic Diseases, Xinjiang Medical University, Urumqi 830011, Xinjiang, China; Department of Immunology, School of Basic Medical Sciences, Xinjiang Medical University, Ur…
  • Department of Pharmacy, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang, China.

Förderung

  • Xinjiang Medical University
  • Xinjiang Uyghur Autonomous Region People's Government

Zitieren

APA

Guan, Y., Bai, D., Bu, N., Hao, W., & Maimaitiyiming, Y. (2026). Programming regulated cell death to engineer whole-tumor-cell vaccines for cancer immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(4), 189640. https://doi.org/10.1016/j.bbcan.2026.189640

Vancouver

Guan Y, Bai D, Bu N, Hao W, Maimaitiyiming Y. Programming regulated cell death to engineer whole-tumor-cell vaccines for cancer immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(4):189640. doi:10.1016/j.bbcan.2026.189640

BibTeX
@article{Guan2026,
  author = {Guan, Yingchao and Bai, Die and Bu, Na and Hao, Wenhui and Maimaitiyiming, Yasen},
  title = {Programming regulated cell death to engineer whole-tumor-cell vaccines for cancer immunotherapy},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2026},
  volume = {1881},
  number = {4},
  pages = {189640},
  doi = {10.1016/j.bbcan.2026.189640}
}
Kostenlos starten →